Clinical Verification of Peptide Biomarkers for Human Aging

Aging Clinical Trial

Official title:

Clinical Verification of Peptide Biomarkers for Human Aging by Standard-Free, Label-Free LC-MS/MS Quanification of Aldehyde-modified Peptides

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02166307
• Other study ID #: deng02
• Status: Completed
• Phase: N/A
• First received: June 16, 2014
• Last updated: June 17, 2014
• Start date: January 2009
• Est. completion date: December 2011

Study information

• Verified date: June 2014
• Source: Beijing Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ministry of Science and Technology
• Study type: Observational

Clinical Trial Summary

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Description:

The procedure of clinical study was:

1. to get plasma samples from hospital;

2. digestion of plasma protein-mixture by trypsin in lab;

3. run mass spectrometry and monitor the amount of target HSA-peptides.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 253
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 23 Years to 72 Years

Eligibility

Inclusion Criteria:

• Cases with different ages

Exclusion Criteria:

• Cases with Diabetes Mellitus and Hepatitis B

Study Design

Observational Model: Case-Only, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Aging

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Institute of Technology

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	measurement of the amount of plasma peptides	The investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.	two years	No